| Company Name: |
Aquigen Bio science Pvt Ltd
|
| Tel: |
+91-7030123794 |
| Email: |
archana.n@aquigenbio.com |
| Products Intro: |
Product Name:Olaparib D5
CAS:2143107-56-4
Purity:97% Package:100mg, 500mg, and 1gm
|
| Company Name: |
Artis Biotech Co. Ltd.
|
| Tel: |
028-67271278 18582380095 |
| Email: |
sales@artisbio.com |
| Products Intro: |
Product Name:Olaparib D5
CAS:2143107-56-4
Purity:99% HPLC Package:1mg 5mg 10mg 50mg 100mg
|
Olaparib D5 manufacturers
- Olaparib-d5
-
- $0.00 / 5mg
-
2025-07-23
- CAS:2143107-56-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Olaparib D5 Basic information |
| Product Name: | Olaparib D5 | | Synonyms: | Olaparib D5;AZD2281 D5;KU0059436 D5;4-(3-(4-(Cyclopropane-1-carbonyl-1,2,2,3,3-d5)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;4-[(3-{4-[(1,2,2,3,3-2H?)cyclopropane-1-carbonyl]piperazine-1-carbonyl}-4-fluorophenyl)methyl]-1,2-dihydrophthalazin-1-one | | CAS: | 2143107-56-4 | | MF: | C24H23FN4O3 | | MW: | 434.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2143107-56-4.mol |  |
| | Olaparib D5 Chemical Properties |
| form | Solid | | color | White to off-white |
| | Olaparib D5 Usage And Synthesis |
| Uses | Olaparib-d5 (AZD2281-d5) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4]. | | References | [1] Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. DOI:10.1021/jm8001263
[2] Senra JM, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Mol Cancer Ther. 2011 Oct;10(10):1949-58. DOI:10.1158/1535-7163.MCT-11-0278
[3] Yasukawa M, et al. Synergetic Effects of PARP Inhibitor AZD2281 in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci. 2016 Feb 24;17(3):272. DOI:10.3390/ijms17030272
[4] Bian X, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 2018 Jan 18;37(3):341-351. DOI:10.1038/onc.2017.326 |
| | Olaparib D5 Preparation Products And Raw materials |
|